Valeant Pharmaceutical Intl Inc. (NYSE:VRX) dropped 6.5% in trade on Friday, after Bloomberg reported that the drugmaker may have a controversial relationship with yet another specialty pharmacy. The NYSE ARCA Pharmaceutical Index (DRG) fell 1.7% during the same time.
